MCID: KDN017
MIFTS: 53

Kidney Cancer malady

Rare diseases, Nephrological diseases, Cancer diseases categories

Aliases & Classifications for Kidney Cancer

About this section

Aliases & Descriptions for Kidney Cancer:

Name: Kidney Cancer 8 42 10 32
Renal Cancer 8 42 44
Renal Cell Carcinoma 1 42 61
Malignant Neoplasm of Kidney Except Pelvis 8
Conventional Renal Cell Carcinoma 61
Malignant Neoplasm of Kidney 61
Malignant Tumour of Kidney 8
 
Renal Adenocarcinoma 42
Carcinoma Renal Cell 44
Renal Cell Carcinoma 61
Renal Cell Cancer 42
Renal Carcinoma 61
Hypernephroma 42


Classifications:



External Ids:

Disease Ontology8 DOID:263
MeSH33 D007680
NCIt39 C3150

Summaries for Kidney Cancer

About this section
MedlinePlus:32 You have two kidneys. they are fist-sized organs on either side of your backbone above your waist. the tubes inside filter and clean your blood, taking out waste products and making urine. kidney cancer forms in the lining of tiny tubes inside your kidneys. kidney cancer becomes more likely as you age. risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. you may have no symptoms at first. they may appear as the cancer grows. see your health care provider if you notice blood in your urine a lump in your abdomen weight loss for no reason pain in your side that does not go away loss of appetite treatment depends on your age, your overall health and how advanced the cancer is. it might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. biologic therapy boosts your body's own ability to fight cancer. targeted therapy uses substances that attack cancer cells without harming normal cells. nih: national cancer institute

MalaCards based summary: Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma and fumarate hydratase deficiency. An important gene associated with Kidney Cancer is IL2 (interleukin 2), and among its related pathways is Renal cell carcinoma. The drugs thalidomide and interferon alfa-2a and the compounds sunitinib and sorafenib have been mentioned in the context of this disorder. Affiliated tissues include the kidney, kidney and prostate, and related mouse phenotype homeostasis/metabolism.

Disease Ontology:8 A urinary system cancer that is located in the kidney.

Wikipedia:64 Kidney cancer is a type of cancer that starts in the cells in the kidney. more...

Related Diseases for Kidney Cancer

About this section

Diseases in the Kidney Cancer family:

Kidney Carcinoma in Situ Kidney Benign Neoplasm

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50)    (show all 102)
idRelated DiseaseScoreTop Affiliating Genes
1renal cell carcinoma31.0VHL, FLCN
2fumarate hydratase deficiency30.8FH
3cystic kidney30.5VHL, FH
4leiomyomatosis30.4FH, VHL
5leiomyoma30.1FH, FLCN
6renal clear cell carcinoma29.8VHL, FH
7colorectal cancer29.4FABP1, IL2, GSTM3
8adenocarcinoma10.7
9prostatitis10.4
10melanoma10.4
11cystadenoma10.3VHL
12obesity10.3
13leiomyomatosis and renal cell cancer10.3
14endotheliitis10.2
15pneumothorax10.2
16leukemoid reaction10.1
17hypoxia10.1
18spontaneous pneumothorax10.1
19paraganglioma10.1FH, VHL
20wilms tumor10.1
21ulcerative colitis10.1
22collecting duct carcinoma10.1
23colitis10.1
24spindle cell carcinoma10.0
25sarcomatoid renal cell carcinoma10.0
26adrenocortical carcinoma10.0
27clear cell papillary renal cell carcinoma10.0
28thyroiditis10.0
29lung cancer10.0
30hematopoietic stem cell transplantation10.0
31hereditary hemorrhagic telangiectasia10.0
32verrucous carcinoma10.0
33angioedema10.0
34interstitial nephritis10.0
35myopathy10.0
36castleman's disease10.0
37wells syndrome10.0
38nephritis10.0
39epididymitis10.0
40oxyphilic adenoma10.0VHL, FH, FLCN
41alveolar soft-part sarcoma10.0
42chronic lymphocytic leukemia10.0
43lymphomatoid granulomatosis10.0
44luteoma10.0
45hypoglycemia10.0
46siderosis10.0
47renal tuberculosis10.0
48psoriasis10.0
49sarcoma10.0
50tuberculosis10.0

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to kidney cancer

Symptoms for Kidney Cancer

About this section

Drugs & Therapeutics for Kidney Cancer

About this section

FDA approved drugs:

(show all 8)
id Drug Name Active Ingredient(s)13 Pharmaceutical Company Approval Date
1
Afinitor13 38 EVEROLIMUS Novartis Approved March 2009
FDA Label: Afinitor
Malady that Drug Treats: renal cell carcinoma/ renal angiomyolipoma associated with tuberous sclerosis complex/ advanced pancreatic neuroendocrine tumor
Indications and Usage:13 AFINITOR is a kinase inhibitor indicated for the treatment of: postmenopausal women with advanced hormone receptor-positive, HER2- negative breast cancer (advanced HR+ BC) in combination with exemestane after failure of treatment with letrozole or anastrozole. (1.1) adults with progressive neuroendocrine tumors of pancreatic origin (PNET) that are unresectable, locally advanced or metastatic. AFINITOR is not indicated for the treatment of patients with functional carcinoid tumors. (1.2) adults with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib. (1.3) adults with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery. The effectiveness of AFINITOR in the treatment of renal angiomyolipoma is based on an analysis of durable objective responses in patients treated for a median of 8.3 months. Further follow-up of patients is required to determine long-term outcomes. (1.4) AFINITOR and AFINITOR DISPERZ are kinase inhibitors indicated for the treatment of: pediatric and adult patients with tuberous sclerosis complex (TSC) who have subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected. The effectiveness is based on demonstration of durable objective response, as evidenced by reduction in SEGA tumor volume. Improvement in diseaserelated symptoms and overall survival in patients with SEGA and TSC has not been demonstrated. (1.5)
DrugBank Targets:11 Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Everolimus is an inhibitor of mammalian target of rapamycin (mTOR), a serine-threonine kinase, downstream of the; PI3K/AKT pathway. The mTOR pathway is dysregulated in several human cancers. Everolimus binds to an intracellular; protein, FKBP-12, resulting in an inhibitory complex formation with mTOR complex 1 (mTORC1) and thus inhibition of; mTOR kinase activity. Everolimus reduced the activity of S6 ribosomal protein kinase (S6K1) and eukaryotic initiation; factor 4E-binding protein (4E-BP1), downstream effectors of mTOR, involved in protein synthesis. S6K1 is a substrate of; mTORC1 and phosphorylates the activation domain 1 of the estrogen receptor which results in ligand-independent; activation of the receptor. In addition, everolimus inhibited the expression of hypoxia-inducible factor (e.g., HIF-1) and; reduced the expression of vascular endothelial growth factor (VEGF). Inhibition of mTOR by everolimus has been shown; to reduce cell proliferation, angiogenesis, and glucose uptake in in vitro and/or in vivo studies.; Constitutive activation of the PI3K/Akt/mTOR pathway can contribute to endocrine resistance in breast cancer. In vitro; studies show that estrogen-dependent and HER2+ breast cancer cells are sensitive to the inhibitory effects of everolimus,; and that combination treatment with everolimus and Akt, HER2, or aromatase inhibitors enhances the anti-tumor activity; of everolimus in a synergistic manner.; Two regulators of mTORC1 signaling are the oncogene suppressors tuberin-sclerosis complexes 1 and 2 (TSC1, TSC2).; Loss or inactivation of either TSC1 or TSC2 leads to activation of downstream signaling. In TSC, a genetic disorder,; inactivating mutations in either the TSC1 or the TSC2 gene lead to hamartoma formation throughout the body.
2
Avastin13 38 BEVACIZUMAB Genentech Approved July 2009
FDA Label: Avastin
Malady that Drug Treats: renal cell carcinoma & Colorectal Cancer
Indications and Usage:13 Avastin is a vascular endothelial growth factor-specific angiogenesis; inhibitor indicated for the treatment of:; Metastatic colorectal cancer, with intravenous 5-fluorouracil-based; chemotherapy for first- or second-line treatment. (1.1); Metastatic colorectal cancer, with fluoropyrimidine- irinotecan- or; fluoropyrimidine-oxaliplatin-based chemotherapy for second-line; treatment in patients who have progressed on a first-line Avastincontaining; regimen. (1.1); Non-squamous non-small cell lung cancer, with carboplatin and paclitaxel; for first line treatment of unresectable, locally advanced, recurrent or; metastatic disease. (1.2); Glioblastoma, as a single agent for adult patients with progressive disease; following prior therapy. (1.3); -Effectiveness based on improvement in objective response rate. No data; available demonstrating improvement in disease-related symptoms or; survival with Avastin.; Metastatic renal cell carcinoma with interferon alfa (1.4); Cervical cancer, in combination with paclitaxel and cisplatin or paclitaxel; and topotecan in persistent, recurrent, or metastatic disease. (1.5); Platinum-resistant recurrent epithelial ovarian, fallopian tube or primary; peritoneal cancer, in combination with paclitaxel, pegylated liposomal; doxorubicin or topotecan (1.6) Limitation of Use: Avastin is not indicated for adjuvant treatment of colon; cancer. (1.1)
DrugBank Targets:11 1. Vascular endothelial growth factor A; 2. Low affinity immunoglobulin gamma Fc region receptor III-B; 3. Complement C1r subcomponent; 4. Complement C1q subcomponent subunit A; 5. Complement C1q subcomponent subunit B; 6. Complement C1q subcomponent subunit C; 7. Low affinity immunoglobulin gamma Fc region receptor III-A; 8. High affinity immunoglobulin gamma Fc receptor I; 9. Low affinity immunoglobulin gamma Fc region receptor II-a; 10. Low affinity immunoglobulin gamma Fc region receptor II-b; 11. Low affinity immunoglobulin gamma Fc region receptor II-c
Mechanism of Action:13 
Target: VEGF
Action: inhibitor
FDA: Bevacizumab binds VEGF and prevents the interaction of VEGF to its receptors (Flt-1 and KDR); 697 on the surface of endothelial cells. The interaction of VEGF with its receptors leads to endothelial; 698 cell proliferation and new blood vessel formation in in vitro models of angiogenesis. Administration; 699 of bevacizumab to xenotransplant models of colon cancer in nude (athymic) mice caused reduction; 700 of microvascular growth and inhibition of metastatic disease progression
3
Inlyta13 38 AXITINIB Pfizer Approved January 2012
FDA Label: Inlyta
Malady that Drug Treats: advanced renal cell carcinoma
Indications and Usage:13 INLYTA is a kinase inhibitor indicated for the treatment of advanced; renal cell carcinoma after failure of one prior systemic therapy. (1)
DrugBank Targets:11 1. Vascular endothelial growth factor receptor 1; 2. Vascular endothelial growth factor receptor 2; 3. Vascular endothelial growth factor receptor 3
Mechanism of Action:13 
Target: receptor tyrosine kinases
Action: inhibitor
FDA: Axitinib has been shown to inhibit receptor tyrosine kinases including vascular endothelial growth; factor receptors (VEGFR)-1, VEGFR-2, and VEGFR-3 at therapeutic plasma concentrations. These; receptors are implicated in pathologic angiogenesis, tumor growth, and cancer progression. VEGFmediated; endothelial cell proliferation and survival were inhibited by axitinib in vitro and in mouse; models. Axitinib was shown to inhibit tumor growth and phosphorylation of VEGFR-2 in tumor xenograft; mouse models.
4
Nexavar13 38 SORAFENIB TOSYLATE Bayer/Onyx Approved December 2005
FDA Label: Nexavar
Malady that Drug Treats: Renal Cell Carcinoma
Indications and Usage:13 NEXAVAR is a kinase inhibitor indicated for the treatment of ; Unresecta ble hepatocellular carcinoma (1.1) adjust thyroid repla cement therapy in patients with thyroid ca ncer. (5.12); Advanced renal cell carcinoma (1.2) Locally recurrent or meta static, progressive, differentiated thyroid carcinoma refractory to ra dioactive iodine treatment (1.3)
DrugBank Targets:11 1. Serine/threonine-protein kinase B-raf; 2. RAF proto-oncogene serine/threonine-protein kinase; 3. Vascular endothelial growth factor receptor 3; 4. Vascular endothelial growth factor receptor 2; 5. Receptor-type tyrosine-protein kinase FLT3; 6. Platelet-derived growth factor receptor beta; 7. Mast/stem cell growth factor receptor Kit; 8. Fibroblast growth factor receptor 1; 9. Proto-oncogene tyrosine-protein kinase receptor Ret; 10. Vascular endothelial growth factor receptor 1
Mechanism of Action:13 
Target: c-CRAF, BRAF and mutant BRAF, KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß
Action: inhibitor
FDA: Sorafenib is a kinase inhibitor that decreases tumor cell proliferation in vitro.; Sorafenib was shown to inhibit multiple intracellular (c-CRAF, BRAF and mutant BRAF) and cell surface; kinases (KIT, FLT- 3, RET, RET/PTC, VEGFR-1, VEGFR- 2, VEGFR- 3, and PDGFR-ß). Several of these; kinases are thought to be involved in tumor cell signaling, angiogenesis and apoptosis. Sorafenib inhibited tumor; growth of HCC, RCC, and DTC human tumor xenografts in immunocompromised mice. Reductions in tumor; angiogenesis were seen in models of HCC and RCC upon sorafenib treatment, and increases in tumor apoptosis; wer e obser ved in models of HCC, RCC, and DTC.
5
Proleukin13 38 ALDESLEUKIN Chiron Approved January 1998
FDA Label: Proleukin
Malady that Drug Treats: Metastatic melanoma
Indications and Usage:13 Proleukin® (aldesleukin) is indicated for the treatment of adults with metastatic renal cell; carcinoma (metastatic RCC).; Proleukin is indicated for the treatment of adults with metastatic melanoma.; Careful patient selection is mandatory prior to the administration of Proleukin. See;  CONTRAINDICATIONS ,  WARNINGS and  PRECAUTIONS sections regarding patient; screening, including recommended cardiac and pulmonary function tests and laboratory; tests.; Evaluation of clinical studies to date reveals that patients with more favorable ECOG; performance status (ECOG PS 0) at treatment initiation respond better to Proleukin, with a; higher response rate and lower toxicity (See  CLINICAL PHARMACOLOGY section,;  CLINICAL STUDIES section and  ADVERSE REACTIONS section). Therefore, selection; of patients for treatment should include assessment of performance status.; Experience in patients with ECOG PS >1 is extremely limited.
DrugBank Targets:11 1. Interleukin-2 receptor subunit beta; 2. Interleukin-2 receptor subunit alpha; 3. Cytokine receptor common subunit gamma
Mechanism of Action:13 
Target: human cells
Action: enhancer of immune response and strnaght ( lymphocyte; mitogenesis, growth of human interleukin-2 dependent cell lines, lymphocyte cytotoxicity, induction of killer cell activity and interferon-gamma production)
FDA: Proleukin® (aldesleukin) has been shown to possess the biological activities of human native; interleukin-2.1,2 In vitro studies performed on human cell lines demonstrate the; immunoregulatory properties of Proleukin, including: a) enhancement of lymphocyte; mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines;; b) enhancement of lymphocyte cytotoxicity; c) induction of killer cell (lymphokine-activated; (LAK) and natural (NK)) activity; and d) induction of interferon-gamma production.; The in vivo administration of Proleukin in animals and humans produces multiple; immunological effects in a dose dependent manner. These effects include activation of; cellular immunity with profound lymphocytosis, eosinophilia, and thrombocytopenia, and the; production of cytokines including tumor necrosis factor, IL-1 and gamma interferon. 3 In vivo; experiments in murine tumor models have shown inhibition of tumor growth.4; The exact; mechanism by which Proleukin mediates its antitumor activity in animals and humans is; unknown.
6
Sutent13 38 SUNITINIB MALATE Pfizer Approved May 2011/ Approved January 2006
FDA Label: Sutent
Malady that Drug Treats: pancreatic neuroendocrine tumors/ Kidney Cancer/Gastrointestinal Stromal Tumors
Indications and Usage:13 SUTENT is a kinase inhibitor indicated for the treatment of:; Gastrointestinal stromal tumor (GIST) after disease progression on or; intolerance to imatinib mesylate. (1.1); Advanced renal cell carcinoma (RCC). (1.2); Progressive, well-differentiated pancreatic neuroendocrine tumors; (pNET) in patients with unresectable locally advanced or metastatic; disease. (1.3)
DrugBank Targets:11 1. Platelet-derived growth factor receptor beta; 2. Vascular endothelial growth factor receptor 1; 3. Mast/stem cell growth factor receptor Kit; 4. Vascular endothelial growth factor receptor 2; 5. Vascular endothelial growth factor receptor 3; 6. Receptor-type tyrosine-protein kinase FLT3; 7. Macrophage colony-stimulating factor 1 receptor; 8. Platelet-derived growth factor receptor alpha
Mechanism of Action:13 
Target: variety of kinases, platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET)
Action: inhibitor
FDA: Sunitinib is a small molecule that inhibits multiple receptor tyrosine kinases (RTKs), some of which are; implicated in tumor growth, pathologic angiogenesis, and metastatic progression of cancer. Sunitinib was; evaluated for its inhibitory activity against a variety of kinases (>80 kinases) and was identified as an inhibitor; of platelet-derived growth factor receptors (PDGFR± and PDGFR²), vascular endothelial growth factor; receptors (VEGFR1, VEGFR2 and VEGFR3), stem cell factor receptor (KIT), Fms-like tyrosine kinase-3; (FLT3), colony stimulating factor receptor Type 1 (CSF-1R), and the glial cell-line derived neurotrophic factor; receptor (RET). Sunitinib inhibition of the activity of these RTKs has been demonstrated in biochemical and; cellular assays, and inhibition of function has been demonstrated in cell proliferation assays. The primary; metabolite exhibits similar potency compared to sunitinib in biochemical and cellular assays.; Sunitinib inhibited the phosphorylation of multiple RTKs (PDGFRbð, VEGFR2, KIT) in tumor xenografts; expressing RTK targets in vivo and demonstrated inhibition of tumor growth or tumor regression and/or; inhibited metastases in some experimental models of cancer. Sunitinib demonstrated the ability to inhibit; growth of tumor cells expressing dysregulated target RTKs (PDGFR, RET, or KIT) in vitro and to inhibit; PDGFRbð- and VEGFR2-dependent tumor angiogenesis in vivo.
7
Torisel13 38 TEMSIROLIMUS Wyeth Approved May 2007
FDA Label: Torisel
Malady that Drug Treats: renal cell carcinoma
Indications and Usage:13 TORISEL® is a kinase inhibitor indicated for the treatment of advanced renal; cell carcinoma. (1)
DrugBank Targets:11 1. Serine/threonine-protein kinase mTOR
Mechanism of Action:13 
Target: mTOR
Action: inhibitor
FDA: Temsirolimus is an inhibitor of mTOR (mammalian target of rapamycin). Temsirolimus binds to; an intracellular protein (FKBP-12), and the protein-drug complex inhibits the activity of mTOR; that controls cell division. Inhibition of mTOR activity resulted in a G1 growth arrest in treated; tumor cells. When mTOR was inhibited, its ability to phosphorylate p70S6k and S6 ribosomal; protein, which are downstream of mTOR in the PI3 kinase/AKT pathway was blocked. In; in vitro studies using renal cell carcinoma cell lines, temsirolimus inhibited the activity of mTOR; and resulted in reduced levels of the hypoxia-inducible factors HIF-1 and HIF-2 alpha, and the; vascular endothelial growth factor.
8
Votrient13 38 PAZOPANIB HYDROCHLORIDE GlaxoSmithKline Approved April 2012/ Approved October of 2009
FDA Label: Votrient
Malady that Drug Treats: soft tissue sarcoma/ renal cell carcinoma
Indications and Usage:13 VOTRIENT is a kinase inhibitor indicated for the treatment of patients with:; advanced renal cell carcinoma. (1); advanced soft tissue sarcoma who have received prior chemotherapy. (1); Limitation of Use: The efficacy of VOTRIENT for the treatment of patients; with adipocytic soft tissue sarcoma or gastrointestinal stromal tu mors has not; been demonstrated.
DrugBank Targets:11 1. Vascular endothelial growth factor receptor 1; 2. Vascular endothelial growth factor receptor 2; 3. Vascular endothelial growth factor receptor 3; 4. Platelet-derived growth factor receptor alpha; 5. Platelet-derived growth factor receptor beta; 6. Mast/stem cell growth factor receptor Kit; 7. Fibroblast growth factor receptor 3; 8. Tyrosine-protein kinase ITK/TSK; 9. Fibroblast growth factor 1; 10. SH2B adapter protein 3
Mechanism of Action:13 
Target: vascular epidermal growth factor receptor (VEGFR) tyrosine kinase
Action: inhibitor
FDA: Pazopanib is a multi-tyrosine kinase inhibitor of vascular endothelial growth factor; receptor (VEGFR)-1, VEGFR-2, VEGFR-3, platelet-derived growth factor receptor (PDGFR)-±; and -², fibroblast growth factor receptor (FGFR)-1 and -3, cytokine receptor (Kit), interleukin-2; receptor-inducible T-cell kinase (Itk), leukocyte-specific protein tyrosine kinase (Lck), and; transmembrane glycoprotein receptor tyrosine kinase (c-Fms). In vitro, pazopanib inhibited; ligand-induced autophosphorylation of VEGFR-2, Kit, and PDGFR-² receptors. In vivo,; pazopanib inhibited VEGF-induced VEGFR-2 phosphorylation in mouse lungs, angiogenesis in; a mouse model, and the growth of some human tumor xenografts in mice.

Drug clinical trials:

Search ClinicalTrials for Kidney Cancer

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS61/NDF-RT40:

Genetic Tests for Kidney Cancer

About this section

Anatomical Context for Kidney Cancer

About this section

MalaCards organs/tissues related to Kidney Cancer:

31
Kidney, Prostate, Endothelial, Testes, Lymph node, Lung, Neutrophil, Eye, Bone, Colon, Liver, Breast, Monocytes, Nk cells, T cells

FMA organs/tissues related to Kidney Cancer:

14
The kidney

Animal Models for Kidney Cancer or affiliated genes

About this section

MGI Mouse Phenotypes related to Kidney Cancer:

35
idDescriptionMGI Source AccessionScoreTop Affiliating Genes
1MP:00053768.0VHL, FH, IL2, FABP1, FLCN, GDF9

Publications for Kidney Cancer

About this section

Articles related to Kidney Cancer:

(show top 50)    (show all 558)
idTitleAuthorsYear
1
Endovascular Extraction of Caval Tumor Thrombus to Facilitate Minimally Invasive Cytoreductive Nephrectomy for Metastatic Kidney Cancer. (25843640)
2015
2
Reply to Marc Bjurlin, Elena Elkin, and William Huang's Letter to the Editor re: Maxine Sun, Andreas Becker, Zhe Tian, et al. Management of Localized Kidney Cancer: Calculating Cancer-specific Mortality and Competing Risks of Death for Surgery and Nonsurgical Management. Eur Urol 2014;65:235-41. (25179937)
2014
3
Kidney cancer: Routine small renal mass needle biopsy should be adopted. (25155789)
2014
4
Metadherin in prostate, bladder, and kidney cancer: A systematic review. (25279212)
2014
5
Decade in review-kidney cancer: Discoveries, therapies and opportunities. (25287783)
2014
6
Urology and nephrology update: bladder and kidney cancer. (24432708)
2014
7
Kidney cancer: Prognostic nutritional index predicts survival. (25311678)
2014
8
Molecular pathways: Fumarate hydratase-deficient kidney cancer--targeting the Warburg effect in cancer. (23633457)
2013
9
Diagnosis and management of BHD-associated kidney cancer. (23703644)
2013
10
Evaluation of awareness of risk factors for kidney cancer among patients presenting to a urology clinic. (24328689)
2013
11
Kidney cancer: New AUA guideline tackles follow-up monitoring of small renal masses. (23712208)
2013
12
Aurora A overexpression and pVHL reduced expression are correlated with a bad kidney cancer prognosis. (23151618)
2012
13
Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. (22321256)
2012
14
Management of kidney cancer in Asia: resource-stratified guidelines from the Asian Oncology Summit 2012. (23117003)
2012
15
Words of wisdom. Re: Long-term survival following partial vs radical nephrectomy among older patients with early-stage kidney cancer. (22748396)
2012
16
Loss of expression of growth differentiation factor-9 (GDF9) in human kidney cancer and regulation of growth and migration of kidney cancer cells by GDF9. (23060562)
2012
17
Re: Thermal ablation vs surgery for localized kidney cancer: a surveillance, epidemiology, and end results (seer) database analysis. (22153419)
2012
18
3rd Pavia international symposium on advanced kidney cancer. (22263875)
2012
19
Kidney cancer: assessing the management of localized kidney cancer. (22430168)
2012
20
Re: Higher perioperative morbidity and in-hospital mortality in patients with end-stage renal disease undergoing nephrectomy for non-metastatic kidney cancer: a population-based analysis. (22784717)
2012
21
Trends in the kidney cancer incidence and mortality in the Slovak and Czech Republics in 1980-2005 - in the context of an international comparison. (21288054)
2011
22
Kidney cancer: Incorporating new parameters into pathological staging of RCC. (21743445)
2011
23
Prognostic model for survival in patients with metastatic renal cell carcinoma: results from the international kidney cancer working group. (21828239)
2011
24
Insulin-like growth factors and risk of kidney cancer in men. (20517306)
2010
25
Management of locally recurrent kidney cancer. (20425632)
2010
26
Kidney Cancer Working Group report. (20870920)
2010
27
Ionizing radiation and kidney cancer among Japanese atomic bomb survivors. (20518663)
2010
28
Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? (19663736)
2009
29
Tensin3 is a negative regulator of cell migration and all four Tensin family members are downregulated in human kidney cancer. (19194507)
2009
30
Kidney cancer in the elderly. (19879478)
2009
31
What is new in kidney cancer? (19954286)
2009
32
NICE recommends kidney cancer drug it previously rejected on cost grounds. (19204038)
2009
33
Canadian kidney cancer forum 2008. (18682767)
2008
34
Antisense attenuation of p21 sensitizes kidney cancer to apoptosis in response to conventional DNA damaging chemotherapy associated with enhancement of phospho-p53. (18499163)
2008
35
Low-dose cyclophosphamide and continuous-infusion interleukin-2 with famotidine in previously treated metastatic melanoma or kidney cancer. (18298334)
2008
36
Major treatment improvements encourage kidney cancer researchers to seek further gains. (18728277)
2008
37
New challenges in kidney cancer therapy: bevacizumab. (17631602)
2007
38
Mechanisms of disease: hereditary leiomyomatosis and renal cell cancer--a distinct form of hereditary kidney cancer. (17287871)
2007
39
18-year recurrence-free survival after extensive surgery for kidney cancer with atrial tumor thrombi. (17880301)
2007
40
Family history and the risk of kidney cancer: a multicenter case-control study in Central Europe. (17548699)
2007
41
Gene expression profiling in kidney cancer: combining differential expression and chromosomal and pathway analyses. (17239277)
2006
42
Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications. (16951219)
2006
43
The effect of hypertension on the risk for kidney cancer in Korean men. (15673312)
2005
44
Allogeneic gene-modified tumour cells in metastatic kidney cancer. Report II. (15709712)
2004
45
Promoter hypermethylation profile of kidney cancer. (15217927)
2004
46
Generation of kidney cancer-specific antitumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding carbonic anhydrase 9. (14977845)
2004
47
Mitochondrial targeting of human 8-oxoguanine DNA glycosylase hOGG1 is impaired by a somatic mutation found in kidney cancer. (12509224)
2002
48
Kidney cancer: the Cytokine Working Group experience (1986-2001): part I. IL-2-based clinical trials. (11917944)
2001
49
Health related quality of life outcomes in patients treated for metastatic kidney cancer: a pilot study. (9112487)
1997
50
Treatment with tumor necrosis factor alpha and interferon alpha of a human kidney cancer xenograft in nude mice: evidence for an anticachectic effect of interferon alpha. (8166454)
1994

Variations for Kidney Cancer

About this section

Expression for genes affiliated with Kidney Cancer

About this section
Search GEO for disease gene expression data for Kidney Cancer.

Pathways for genes affiliated with Kidney Cancer

About this section

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

idSuper pathways (with members indented)ScoreTop Affiliating Genes
19.3VHL, FH, FLCN

Compounds for genes affiliated with Kidney Cancer

About this section
Sources:
44Novoseek, 50PharmGKB, 11DrugBank
See all sources

Compounds related to Kidney Cancer according to GeneCards Suite gene sharing:

idCompoundScoreTop Affiliating Genes
1sunitinib44 50 1112.0VHL, IL2
2sorafenib44 50 1111.9IL2, VHL
3succinate449.8VHL, FH
4alpha-ketoglutarate449.7VHL, FH
5fumarate44 1110.6VHL, FH, IL2
6rapamycin449.5VHL, IL2, FLCN
7phosphoenolpyruvate44 1110.2FH, FABP1

GO Terms for genes affiliated with Kidney Cancer

About this section

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

idNameGO IDScoreTop Affiliating Genes
1protein ubiquitinationGO:00165679.4RNF139, VHLL, VHL
2cellular response to hypoxiaGO:00714569.2VHL, FABP1
3negative regulation of cell growthGO:00303089.2NDUFA13, FLCN, GDF9
4positive regulation of cell proliferationGO:00082849.1IL2, FABP1, GDF9
5negative regulation of apoptotic processGO:00430669.1FABP1, IL2, VHL
6small molecule metabolic processGO:00442818.1NDUFA13, GSTM3, FH, FABP1

Sources for Kidney Cancer

About this section
2CDC
12ExPASy
13FDA
14FMA
22GTR
23HGMD
24HMDB
25ICD10
26ICD10 via Orphanet
27ICD9CM
28IUPHAR
29KEGG
33MeSH
34MESH via Orphanet
35MGI
38NCI
39NCIt
40NDF-RT
43NINDS
44Novoseek
46OMIM
47OMIM via Orphanet
51PubMed
52QIAGEN
57SNOMED-CT via Orphanet
61UMLS
62UMLS via Orphanet